GNPDA1 (glucosamine-6-phosphate deaminase 1) catalyzes the reversible conversion of glucosamine-6-phosphate into fructose-6-phosphate and ammonia, a critical regulatory step in hexosamine biosynthesis that controls UDP-GlcNAc production 1. This enzyme functions bidirectionally: under standard conditions it primarily diverts GlcN6P back to glycolysis, but when hexosamine biosynthesis is blocked, it reverses to maintain UDP-GlcNAc levels for glycoprotein and hyaluronan synthesis 1. GNPDA1 also plays roles in ammonium metabolism, particularly in cancer cells where altered hexosamine pathway flux affects protein N-glycosylation and O-GlcNAcylation 2. Clinically, GNPDA1 expression correlates with multiple disease states: it is upregulated in colorectal cancer cells treated with anti-cancer agents 3, associated with insulin resistance in obese children 4, and significantly elevated in head and neck squamous cell carcinoma where high expression predicts poor prognosis and correlates with immune evasion mechanisms 5. GNPDA1 also serves as a prognostic methylation marker in epithelial ovarian cancer 6. Additionally, upregulation of GNPDA1 is associated with phlegm-dampness constitution in traditional Chinese medicine, conferring increased susceptibility to metabolic diseases including obesity, diabetes, and metabolic syndrome 7.